Oncotelic Therapeutics, Inc. filed 1 current report with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-07-14. Each change below is quoted from the filing and linked to it.
Every change, newest first
Reported
If the uplisting does occur not by June 30, 2027, or such period as extended by the Board, or, the recipient's continuous service terminates before six months following the uplisting, then the RSUs would expire and automatically be forfeited.
Oncotelic Therapeutics, Inc.'s funding history
Find people with the same kind of experience as the senior executive at Oncotelic Therapeutics, Inc., with the record behind each one.
Find candidates like senior executive at Oncotelic Therapeutics, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Oncotelic Therapeutics, Inc. is in the news or changes leadership.
Get an alert when Oncotelic Therapeutics, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Oncotelic Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.